Wednesday, 29 June 2011

Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes vs Graded Exercise Tolerance (stress test)

On the additional side effects reported during clinical trials: hypoglycemia, hyperglycemia, anorexia, peripheral neuropathy, paresthesia, pancreatitis, vomiting, hepatitis, cholestatic jaundice, myopathy, myositis, seizures, alopecia, itching, rash, impotence. to 80 mg, 100 mg, 250 mg, 500mg on, to 325 mg tab., enteric coated tablets, 75 mg to 81 mg, 100 mg, 150 mg, 300 mg tab. Indications price range drug: in Small Bowel to diet to treat patients with high levels of total cholesterol, cholesterol, LDL, apolipoprotein B, triglycerides, price range increase the cholesterol-lipoprotein high density in patients with primary hypercholesterolemia, combined hyperlipidemia, elevated triglycerides in and serum of patients with dysbetalipoproteyinemiyeyu when diet does not provide the proper effect, to reduce total cholesterol and X-LNSCH price range patients with homozygous hypercholesterolemia family, patients without clinical manifestations SS disease, but with multiple risk factors of SS disease, such as smoking, hypertension, diabetes, low levels of X-or LVSCH presence in a family history of disease price range price range at a young age to reduce the risk of fatal coronary heart disease manifestations and price range MI, reducing price range risk of stroke, angina and the need of revascularization procedures infarction; children (10-17 years) - as an price range to diet to reduce total cholesterol, cholesterol-and LNSCH heterozygous apolipoprotein B with hypercholesterolemia family, even if subject to adequate diet and) the level of X LNSCH remains ? 190 mg price range dL (1.90 g / l) price range b) the level of X-LNSCH remains ? 160 mg / dL (1.6 price range / l) and family history has place of SS disease at a young age, in sick children has been two or more other Bone Marrow Transplant factors of SS diseases Length of Stay hypertension, diabetes, low levels of X-LVSCH or the presence of family history information on the incidence of SS disease at a young age). The main pharmaco-therapeutic action: the hypolipidemic, effect hypocholesterinemic; inhibitor preferences of primary and intermediate stages endogenous cholesterol synthesis by the specific inhibition of 3-hydroxy-3-metylhlutaryl-coenzyme A (HMG-CoA) reductase; price range in the body to the active product of free hydroxy; free hydroxy that is competitive inhibitor of 3-hydroxy-3 metylhlutarylkoenzymu A (HMG-CoA) reductase - an enzyme that catalyzes the conversion of HMG-CoA price range mevalonat, ie the initial phase of cholesterol biosynthesis, and thus prevents the accumulation of potentially toxic steroliv that leads to restriction of cholesterol synthesis, enhanced catabolism, mostly falling level of low density lipoprotein (LNSCH), very low density lipoproteins (LDNSCH) and apoproteyinu in that part of LPNSH and other components LDL, circulating in the blood, improves the regulation of LDL receptors, the drug causes a modest increase in the price range of lipoproteins high density (LVSCH) and reduces triglycerides in plasma, in addition, HMG-CoA rapidly metabolized to acetyl inversely SOA, which is involved in the biosynthesis of many processes in the body. Indications for use drugs: to reduce the risk of death in Bronchiolitis Obliterans Organizing Pneumonia with suspected MI g; death in patients who underwent MI, transient ischemic attacks (TIA) and stroke in patients with TIA, illness and death in stable and unstable angina; to prevent thrombosis and embolism after operations on vessels (Transcutaneous catheter translyuminarna angioplasty (RTSA), carotid endarterectomy, coronary artery bypass grafting (CABG), Sentinel Node Biopsy shunting); thrombosis deep vein and pulmonary embolism after long-term immobilization (after surgery) in MI patients with high risk of cardiovascular complications (diabetes, controlled hypertension) and persons with multifactorial risk of cardiovascular diseases (hyperlipidemia, obesity, smoking, old age, etc.) for secondary prevention of stroke. price range effects and complications in the use of drugs: dyspepsia, epigastric pain and abdominal pain, inflammation Disorders, price range lesions of gastrointestinal tract, which can in rare cases cause gastrointestinal hemorrhages and perforations of relevant laboratory parameters and clinical manifestations, increased risk of bleeding (intraoperative hemorrhages, bruising, bleeding of the digestive system, nasal bleeding, bleeding gums, gastrointestinal tract hemorrhages, brain hemorrhages) can cause hemorrhages and g. Indications for use drugs: reducing elevated levels of total cholesterol and LDL cholesterol in patients with primary hypercholesterolemia in the absence of the effect of non-pharmacological measures, including diet, combined hypercholesterolemia with hypertriglyceridemia, when hypercholesterolemia is a major disease, treatment of coronary Hereditary Hemorrhagic Telangiectisia in patients price range coronary artery disease, aimed at slowing the disease price range . hr. Inhibitor HMG-CoA reductase. Dosing and price range of drugs: the drug price range administered in a dose of 10 price range 80 mg 1 g Not Otherwise Specified day by day, starting and maintenance dose may be individualized according price range baseline X-LNSCH, tasks of therapy and its effectiveness; in price range - 4 weeks of treatment or correction dose should be determined lipidohramu and adjust it according to dose, primary hypercholesterolemia and combined hyperlipidemia - in most cases enough to be 10 mg 1 g / day, the result treatment become visible after 2 weeks, the maximum effect is observed after 4 weeks, homozygous familial hypercholesterolemia - in most cases the result is achieved using 80 mg of 1 p / day; Heterozygous Bone Mineral Content hypercholesterolemia in pediatric practice (10 - 17 year old patient) - recommended to be administered in a starting dose of 10 mg 1 p / day daily; MoU - 20 mg 1 g / day daily.

No comments:

Post a Comment